Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash from Operations: 2022-2025

Historic Cash from Operations for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -$14.1 million.

  • Phathom Pharmaceuticals' Cash from Operations rose 77.80% to -$14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$225.2 million, marking a year-over-year increase of 8.85%. This contributed to the annual value of -$266.8 million for FY2024, which is 93.90% down from last year.
  • According to the latest figures from Q3 2025, Phathom Pharmaceuticals' Cash from Operations is -$14.1 million, which was up 77.50% from -$62.7 million recorded in Q2 2025.
  • Over the past 5 years, Phathom Pharmaceuticals' Cash from Operations peaked at -$14.1 million during Q3 2025, and registered a low of -$84.9 million during Q1 2025.
  • Moreover, its 3-year median value for Cash from Operations was -$62.7 million (2025), whereas its average is -$51.5 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first tumbled by 218.56% in 2024, then surged by 77.80% in 2025.
  • Quarterly analysis of 4 years shows Phathom Pharmaceuticals' Cash from Operations stood at -$41.0 million in 2022, then dropped by 6.72% to -$43.8 million in 2023, then tumbled by 44.89% to -$63.5 million in 2024, then surged by 77.80% to -$14.1 million in 2025.
  • Its last three reported values are -$14.1 million in Q3 2025, -$62.7 million for Q2 2025, and -$84.9 million during Q1 2025.